Group 2C: HER2+, HER2-low, & Triple Negative Breast Cancer; Clinical Trials; Antibody-drug Conjugates

Poster #PS08-09: Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE).

Poster #PO1-19-10: Durvalumab + datopotamab deruxtecan in patients with PD-L1 positive advanced/metastatic triple-negative breast cancer: Arm 8 of the phase 1b/2, open label, platform BEGONIA study.